Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 15, 2026 | May 15, 2026 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director | June 10, 2026 | June 10, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP & Chief Accounting Officer | February 26, 2021 | March 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date May 15, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14 | Direct | 31,250 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Rapport Therapeutics, Inc.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10 | Direct | 15,200 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date February 26, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,884 |
Ending reported balance
After 2021-03-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-02-26 · Tax withholding · Disposed 2,218 · Balance 12,666 Row 2 · 2021-03-01 · Sale · Disposed 1,026 · Balance 11,640 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77). F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2021-03-01 · Sale · Disposed 610 · Balance 11,030 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95). Row 4 · 2021-03-01 · Sale · Disposed 915 · Balance 10,115 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85). Row 5 · 2021-03-01 · Sale · Disposed 231 · Balance 9,884 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27). |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 169 |
Reported balance
Holding disclosure · report date 2021-02-26 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 169 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77).
F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95).
F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85).
F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2020 Filed Feb 19, 2020 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,248 | $241.50 | $301,392.00 |
DisclosureSEC source: 0001209191-20-010554 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,440 Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,102 | $247.93 | $273,218.86 |
DisclosureSEC source: 0001209191-20-008895 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,688 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $247.93 (range $247.58 to $248.55). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,120 | $246.84 | $276,460.80 |
DisclosureSEC source: 0001209191-20-008895 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,790 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $246.84 (range $246.46 to $247.38). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,700 | $245.89 | $418,013.00 |
DisclosureSEC source: 0001209191-20-008895 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,910 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $245.89 (range $245.39 to $246.30). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,560 | $244.90 | $382,044.00 |
DisclosureSEC source: 0001209191-20-008895 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,610 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $244.90 (range $244.37 to $245.33). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 380 | $243.59 | $92,564.20 |
DisclosureSEC source: 0001209191-20-008895 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,170 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $243.59 (range $243.29 to $244.28). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 22:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 4,673 | $240.95 | $1,125,959.35 |
DisclosureSEC source: 0001209191-20-008895 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,550 Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 466 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-007523 · doc4.xml · derivative · entry 9 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,587 Underlying: Common Stock · 466 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 31 | $242.47 | $7,516.57 |
DisclosureSEC source: 0001209191-20-007523 · doc4.xml · nonDerivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,223 F4 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 92 | $240.46 | $22,122.32 |
DisclosureSEC source: 0001209191-20-007523 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,254 F4 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F6 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $240.46 (range $240.11 to $240.84). Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 343 | $238.73 | $81,884.39 |
DisclosureSEC source: 0001209191-20-007523 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,346 F4 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F5 · price: Open market sales reported on this line occurred at a weighted average price of $238.73 (range $238.15 to $239.14). F6 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 466 | $187.53 | $87,388.98 |
DisclosureSEC source: 0001209191-20-007523 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 3,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007523 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,223 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2021. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007523 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,997 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. The earned performance shares will vest in installments beginning on 02/24/2020. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 6,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007523 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,079 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 809 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-20-006959 · doc4.xml · derivative · entry 10 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,236 Underlying: Common Stock · 809 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,290 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-20-006959 · doc4.xml · derivative · entry 9 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,290 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 210 | $232.75 | $48,877.50 |
DisclosureSEC source: 0001209191-20-006959 · doc4.xml · nonDerivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,759 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $232.75 (range $232.26 to $233.21). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 630 | $231.46 | $145,819.80 |
DisclosureSEC source: 0001209191-20-006959 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,969 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $231.46 (range $231.21 to $231.63). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 809 | $231.03 | $186,903.27 |
DisclosureSEC source: 0001209191-20-006959 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,599 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 240 | $230.28 | $55,267.20 |
DisclosureSEC source: 0001209191-20-006959 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,408 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.28 (range $229.92 to $230.53). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 210 | $228.91 | $48,071.10 |
DisclosureSEC source: 0001209191-20-006959 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,648 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $228.91 (range $228.37 to $229.24). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 809 | $86.52 | $69,994.68 |
DisclosureSEC source: 0001209191-20-006959 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,290 | $91.05 | $117,454.50 |
DisclosureSEC source: 0001209191-20-006959 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,396 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-006304 · doc4.xml · derivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,053 Underlying: Common Stock · 1,396 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,396 | $238.65 | $333,155.40 |
DisclosureSEC source: 0001209191-20-006304 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,759 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,396 | $187.53 | $261,791.88 |
DisclosureSEC source: 0001209191-20-006304 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 860 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-20-003458 · doc4.xml · derivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,719 Underlying: Common Stock · 860 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/12/2016. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 860 | $229.38 | $197,266.80 |
DisclosureSEC source: 0001209191-20-003458 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,759 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 860 | $90.29 | $77,649.40 |
DisclosureSEC source: 0001209191-20-003458 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,750 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-20-003064 · doc4.xml · derivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,750 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 13,750 | $231.89 | $3,188,487.50 |
DisclosureSEC source: 0001209191-20-003064 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,759 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $231.89 (range $231.89 to $231.90). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 13,750 | $131.89 | $1,813,487.50 |
DisclosureSEC source: 0001209191-20-003064 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to buy) · Derivative | 2,427 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-20-001770 · doc4.xml · derivative · entry 13 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,045 Underlying: Common Stock · 2,427 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to buy) · Derivative | 2,578 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-20-001770 · doc4.xml · derivative · entry 12 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,579 Underlying: Common Stock · 2,578 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/12/2016. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to buy) · Derivative | 3,867 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-20-001770 · doc4.xml · derivative · entry 11 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,290 Underlying: Common Stock · 3,867 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to buy) · Derivative | 16,758 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-20-001770 · doc4.xml · derivative · entry 10 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,758 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $220.07 | $22,007.00 |
DisclosureSEC source: 0001209191-20-001770 · doc4.xml · nonDerivative · entry 8 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,759 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,648 | $219.37 | $2,774,591.76 |
DisclosureSEC source: 0001209191-20-001770 · doc4.xml · nonDerivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,859 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $219.37 (range $219.07 to $219.82). Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,040 | $218.70 | $2,195,748.00 |
DisclosureSEC source: 0001209191-20-001770 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,507 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $218.70 (range $218.07 to $219.06). Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,842 | $217.68 | $618,646.56 |
DisclosureSEC source: 0001209191-20-001770 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,547 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $217.68 (range $217.08 to $218.02). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,427 | $86.52 | $209,984.04 |
DisclosureSEC source: 0001209191-20-001770 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,578 | $90.29 | $232,767.62 |
DisclosureSEC source: 0001209191-20-001770 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,867 | $91.05 | $352,090.35 |
DisclosureSEC source: 0001209191-20-001770 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 16,758 | $109.14 | $1,828,968.12 |
DisclosureSEC source: 0001209191-20-001770 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 161 | $165.41 | $26,631.01 |
DisclosureSEC source: 0001209191-19-030950 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,759 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 160 | $188.70 | $30,192.00 |
DisclosureSEC source: 0001209191-19-012010 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,759 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 984 | $187.10 | $184,106.40 |
DisclosureSEC source: 0001209191-19-012010 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,919 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $187.10 (range $186.95 to $187.42). Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,668 | $186.72 | $311,448.96 |
DisclosureSEC source: 0001209191-19-012010 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,903 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $186.72 (range $185.93 to $186.93). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 715 | $181.09 | $129,479.35 |
DisclosureSEC source: 0001209191-19-009630 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,571 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $181.09 (range $180.88 to $181.36). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.